Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Synthesis of potent water-soluble tissue transglutaminase inhibitors.

Literature DB >> 18812257

Synthesis of potent water-soluble tissue transglutaminase inhibitors.

Martin Griffin¹, Alexandre Mongeot, Russell Collighan, Robert E Saint, Richard A Jones, Ian G C Coutts, Daniel L Rathbone.

Abstract

Dipeptide-based sulfonium peptidylmethylketones derived from 6-diazo-5-oxo-L-norleucine (DON) have been investigated as potential water-soluble inhibitors of extracellular transglutaminase. The lead compounds were prepared in four steps and exhibited potent activity against tissue transglutaminase.

Entities: Chemical Gene

Mesh：

Substances：

Year: 2008 PMID： 18812257 DOI： 10.1016/j.bmcl.2008.09.006

Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823

Keyword Cloud
Cited

22 in total

1. Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.

Authors: Cristina Antonella Nadalutti; Ilma Rita Korponay-Szabo; Katri Kaukinen; Martin Griffin; Markku Mäki; Katri Lindfors
Journal: Cell Mol Life Sci Date: 2013-08-28 Impact factor: 9.261

2. Indwelling catheters and medical implants with FXIIIa inhibitors: A novel approach to the treatment of catheter and medical device-related infections.

Authors: Nooshin Daneshpour; Russell Collighan; Yvonne Perrie; Peter Lambert; Dan Rathbone; Deborah Lowry; Martin Griffin
Journal: Eur J Pharm Biopharm Date: 2012-09-25 Impact factor: 5.571

3. Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.

Authors: T Rauhavirta; S-W Qiao; Z Jiang; E Myrsky; J Loponen; I R Korponay-Szabó; H Salovaara; J A Garcia-Horsman; J Venäläinen; P T Männistö; R Collighan; A Mongeot; M Griffin; M Mäki; K Kaukinen; K Lindfors
Journal: Clin Exp Immunol Date: 2011-01-14 Impact factor: 4.330

4. Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.

Authors: Zhuo Wang; Russell J Collighan; Kamila Pytel; Daniel L Rathbone; Xiaoling Li; Martin Griffin
Journal: J Biol Chem Date: 2012-02-01 Impact factor: 5.157

5. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.

Authors: Tiina Rauhavirta; Mikko Oittinen; Rami Kivistö; Pekka T Männistö; J Arturo Garcia-Horsman; Zhuo Wang; Martin Griffin; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal: J Clin Immunol Date: 2012-08-10 Impact factor: 8.317

6. Pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1) gene is suppressed by transglutaminase 2 activation.

Authors: Ayako Miura; Yuki Kambe; Kazuhiko Inoue; Hideki Tatsukawa; Takashi Kurihara; Martin Griffin; Soichi Kojima; Atsuro Miyata
Journal: J Biol Chem Date: 2013-09-17 Impact factor: 5.157

7. Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors: Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal: J Med Chem Date: 2017-09-14 Impact factor: 7.446